Treating obesity by quelling inflammation in the brain

Preclinical data suggest NLRP3 could be an important new target for treating obesity. Among the benefits could be oral dosing with fewer side effects than GLP-1s and an improved cardioprotective profile. But investors shouldn’t expect to see efficacy as quickly for the anti-inflammatory mechanism as observed with incretin-based therapies.

The NLRP3 inflammasome has been implicated as a driver of pathology in a variety of diseases, ranging from cancer to asthma, heart disease and metabolic-associated steatohepatitis (MASH)...